Dalton et al., 2007 - Google Patents
The role of hepatitis E virus testing in drug‐induced liver injuryDalton et al., 2007
View PDF- Document ID
- 4112200946552421839
- Author
- Dalton H
- Fellows H
- Stableforth W
- Joseph M
- Thurairajah P
- Warshow U
- Hazeldine S
- Remnarace R
- Ijaz S
- Hussaini S
- Bendall R
- Publication year
- Publication venue
- Alimentary pharmacology & therapeutics
External Links
Snippet
Background Locally acquired hepatitis E is an emerging infection in developed countries and can be misdiagnosed as drug‐induced liver injury. Aim To study the role of hepatitis E virus (HEV) testing in drug‐induced liver injury. Methods Retrospective review of a cohort of …
- 206010072268 Drug-induced liver injury 0 title abstract description 82
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/576—Immunoassay; Biospecific binding assay for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay for hepatitis non-A, non-B hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dalton et al. | The role of hepatitis E virus testing in drug‐induced liver injury | |
| Mehta et al. | Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States | |
| Ioannou et al. | Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis | |
| Green et al. | Coxsackie B virus serology and type 1 diabetes mellitus: a systematic review of published case‐control studies | |
| Pritchard et al. | Impact of vaccination on SARS-CoV-2 cases in the community: a population-based study using the UK’s COVID-19 Infection Survey | |
| Woolson et al. | Extra‐hepatic manifestations of autochthonous hepatitis E infection | |
| Zanini et al. | Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak | |
| Nelson et al. | The epidemiology of hepatitis E virus infections in developed countries and among immunocompromised patients | |
| Junaid et al. | Epidemiology and associated risk factors of hepatitis e virus infection in plateau state, Nigeria | |
| Schöllkopf et al. | Hepatitis C infection and risk of malignant lymphoma | |
| Widdowson et al. | Cluster of cases of acute hepatitis associated with hepatitis E virus infection acquired in the Netherlands | |
| Stepanova et al. | Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity | |
| Huang et al. | Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link? | |
| Tanaka et al. | Primary biliary cirrhosis–Autoimmune hepatitis overlap syndrome: A rationale for corticosteroids use based on a nation‐wide retrospective study in Japan | |
| Lo Re III et al. | Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection | |
| Nezu et al. | Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis | |
| Chalupa et al. | Endemic hepatitis E in the Czech Republic | |
| Tripathy et al. | Study of a hepatitis E virus outbreak involving drinking water and sewage contamination in Shimla, India, 2015–2016 | |
| de Sanjose et al. | Role of hepatitis C virus infection in malignant lymphoma in Spain | |
| Buescher et al. | Hepatitis E seroprevalence and viremia rate in immunocompromised patients: a systematic review and meta‐analysis | |
| Teschke et al. | Drug-and herb-induced liver injury in clinical and translational hepatology: causality assessment methods, quo vadis? | |
| Nicastro et al. | The impact of severe acute respiratory syndrome coronavirus type 2 on children with liver diseases: a joint European society for pediatric gastroenterology, hepatology and nutrition and society of pediatric liver transplantation position paper | |
| Cervera et al. | A prospective survey of human herpesvirus-6 primary infection in solid organ transplant recipients | |
| Crespo et al. | Early non‐invasive selection of patients at high risk of severe hepatitis C recurrence after liver transplantation | |
| Fontana et al. | Incidence of hepatitis e infection in American patients with suspected drug-induced liver injury is low and declining: The DILIN prospective study |